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Reza Razavi, MD, Steve Niederer, DPHIL, Christopher Aldo Rinaldi, MDABSTRACTOBJECTIVES The purpose of this study was to identify the optimal pacing site for the left ventricular (LV) lead in
ischemic patients with poor response to cardiac resynchronization therapy (CRT).
BACKGROUND LV endocardial pacing may offer beneﬁt over conventional CRT in ischemic patients.
METHODS We performed cardiac magnetic resonance, invasive electroanatomic mapping (EAM), and measured the
acute hemodynamic response (AHR) in patients with existing CRT systems.
RESULTS In all, 135 epicardial and endocardial pacing sites were tested in 8 patients. Endocardial pacing was
superior to epicardial pacing with respect to mean AHR (% change in dP/dtmax vs. baseline) (11.81 [-7.2 to 44.6] vs.
6.55 [-11.0 to 19.7]; p ¼ 0.025). This was associated with a similar ﬁrst ventricular depolarization (Q-LV) (75 ms [13 to
161 ms] vs. 75 ms [25 to 129 ms]; p ¼ 0.354), shorter stimulation–QRS duration (15 ms [7 to 43 ms] vs. 19 ms
[5 to 66 ms]; p ¼ 0.010) and shorter paced QRS duration (149 ms [95 to 218 ms] vs. 171 ms [120 to 235 ms];
p < 0.001). The mean best achievable AHR was higher with endocardial pacing (25.64  14.74% vs. 12.64  6.76%;
p ¼ 0.044). Furthermore, AHR was signiﬁcantly greater pacing the same site endocardially versus epicardially
(15.2  10.7% vs. 7.6  6.3%; p ¼ 0.014) with a shorter paced QRS duration (137  22 ms vs. 166  30 ms; p < 0.001)
despite a similar Q-LV (70  38 ms vs. 79  34 ms; p ¼ 0.512). Lack of capture due to areas of scar (corroborated
by EAM and cardiac magnetic resonance) was associated with a poor AHR.
CONCLUSIONS In ischemic patients with poor CRT response, biventricular endocardial pacing is superior to
epicardial pacing. This may reﬂect accessibility to sites that cannot be reached via coronary sinus anatomy and/or
by access to more rapidly conducting tissue. Furthermore, guidance to the optimal LV pacing site may be aided
by modalities such as cardiac magnetic resonance to target delayed activating sites while avoiding scar. (J Am Coll
Cardiol EP 2016;2:799–809) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).C ardiac resynchronization therapy (CRT) is ahighly effective treatment for patients withheart failure, severe left ventricular (LV)
impairment and a prolonged QRS duration (1–3).
Despite advancing techniques a substantial proportion
of individuals do not derive clinical beneﬁt (4).
Improving CRT response is particularly challenging inischemic patients because epicardial LV lead place-
ment within myocardial scar has a negative impact
(5,6) and avoiding scarred regions may improve CRT
response (7). Furthermore, correction of electrical dys-
synchrony through targeting of the latest point of acti-
vation may be important in improving CRT response
(8,9). Stimulation of the LV endocardium (LVendo),
AB BR E V I A T I O N S
AND ACRONYM S
AHR = acute hemodynamic
response
CMR = cardiac magnetic
resonance
CRT = cardiac
resynchronization therapy
EAM = electroanatomic
mapping
LV = left ventricle/ventricular
LVendo = left ventricular
endocardium
LVepi = optimal epicardial
response
LVepi1 = implanted LV lead
LVepi2 = temporary LV lead
Q-LV = ﬁrst ventricular
depolarization
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801which is not constrained to the epicardial coronary
venous anatomy, may provide superior hemody-
namics (10–12) and improved CRT response, which
may be of particular beneﬁt in ischemic patients and
nonresponders to conventional CRT (12–14). The site
of optimal LVendo stimulation is highly variable in
ischemic and nonischemic groups (15) with no reliable
method to guide optimal LVendo lead placement. Car-
diacmagnetic resonance (CMR) could potentially iden-
tify the target for LV lead placement, being able to
delineate scar and dyssynchrony (7). Endocardial con-
tact mapping can demonstrate exquisite detail of
endocardial activation as well as location and size of
myocardial scar. Because patients with ischemic car-
diomyopathy and myocardial scar have the poorest
response to CRT and themost to gain fromLVendo pac-
ing, advanced imaging andmappingmodalitiesmay be
able to guide the optimal site for endocardial LV lead
delivery.SEE PAGE 810Wehypothesized that in a group of ischemic patients
(with demonstrable myocardial scar on CMR) and a
high prevalence of CRT nonresponse, LVendo pacing
would produce a superior hemodynamic response
compared with the optimal epicardial response
(LVepi). Furthermore, by pacing multiple sites, we
sought to investigate whether the optimal site of LV
stimulation (both epicardially and endocardially) could
be predicted on the basis of scar and/or the latest point
of electrical activation. By comparing endocardial
contact mapping data with CMR, we further sought to
elucidate the mechanisms of improved response with
LVendo pacing and whether these imaging modalities
could be used to guide the optimal LVendo pacing sites.
METHODS
The study complied with the Declaration of Helsinki
and the protocol was approved by the local ethics
committee. Informed consent was obtained from
each patient. Patients with ischemic cardiomyopathy
(judged by signiﬁcant coronary artery disease and
myocardial ﬁbrosis on CMR), QRS duration of
<150 ms, and previously implanted CRT (mean
duration of implant 26  21 months) have a pheno-
type of suboptimal response to CRT and were inten-
tionally selected for study (3). Baseline assessment
before CRT implant included clinical assessment
(New York Heart Association functional class), 12-lead
electrocardiogram, and 2-dimensional echocardiog-
raphy. Patients underwent an extensive endocardial
mapping protocol and acute hemodynamic study.
CMR data were compared with contact mapping andhemodynamic data ﬁndings to compare
optimal LVendo and LVepi pacing locations.
HEMODYNAMIC AND ELECTROANATOMIC
STUDY. Cases were performed under
conscious sedation (mean 2.5 mg midazolam
and 3 mg morphine) between March and
December 2014. Patients with a mechanical
aortic valve or signiﬁcant peripheral vascular
disease were excluded. CMR before CRT was
performed with a standardized protocol
including cine imaging and delayed enhance-
ment sequences in both long and short axis
views. Delayed enhancement was performed
10 to 15 min after administration of 0.2 mmol/
kg Gadovist (Bayer Healthcare, Berlin, Ger-
many) to identify myocardial ﬁbrosis. Contact
LV endocardial scar mapping was performed
in sinus rhythm with a roving decapolar cath-
eter (6-F Livewire medium sweep 115 cm; St Jude
Medical, Sylmar, California) via femoral arterial access
with a retrograde aortic approach and displayed using
EnSite Velocity NavX system (St Jude Medical, Inc., St
Paul, Minnesota). Multiple contact points were taken
to create the endocardial geometry (mean 328  133)
with particular focus of delineating areas of scar.
Points with a sensed bipolar electrogram amplitude
of <0.5 mV were deﬁned as scar and colored grey,
points >1.5 mV were deﬁned as representing healthy
tissue and colored purple and those points in between
deﬁned as border zone with a color range (16).
Temporary placement of a high right atrial quad-
ripolar catheter was used for atrial sensing. Initially,
the optimal epicardial site with atrial synchronous
biventricular pacing was assessed using the patient’s
chronically implanted LV lead (LVepi1) and a second,
temporary epicardial LV lead placed via the femoral
vein (LVepi2) to allow multiple epicardial pacing
sites from different veins and along the same vein
(Figure 1). The optimal endocardial site was then
assessed using the roving LV endocardial decapolar
catheter. The LV was divided into 12 locations (ante-
rior, lateral, inferior, septal at basal, mid and apical
levels) and randomized (Microsoft Excel). We plan-
ned to pace in each of these 12 regions per patient; in
addition, extra positions in or adjacent to scar on the
EAM were obtained. The mean number of endocardial
positions was 10.4  4.8 (range 4 to 18) and each
patient had a minimum dataset comprising an
anterior, lateral, inferior, and septal position. In all
patients, we performed biventricular pacing at cor-
responding positions endocardially and epicardially
at 2 sites (i.e., LVendo pacing opposite both epi1 and
epi2). We used ﬂuoroscopy (both left anterior oblique
FIGURE 1 Fluoroscopic and Electroanatomic Imaging of the Study Protocol
(A) Fluoroscopic image of the invasive protocol. (B) Corresponding electroanatomic endocardial, contact scar map using a decapolar left
ventricular (LV) catheter and the EnSite Velocity NavX system (St. Jude Medical, Inc., St. Paul, Minnesota); right anterior oblique (left) and left
anterior oblique (right) projections. Data points with a sensed electrogram amplitude of <0.5 mV were deﬁned as scar (grey), those with
voltage of >1.5 mV were deﬁned as healthy tissue (purple) and those points in between were in the scar border zone with a color range.
The anterior surface of the heart in the left panel has been removed to see the location of the endocardial catheter (green) and distal tip
(green circle). The epicardial pacing (LVepi)2 lead is in an anterior vein and displayed in blue on the EAM. In addition, the position of the
implanted (LVepi)1 lead is shown on ﬂuoroscopy and has been superimposed on the electroanatomic map in both views. Epi¼ epicardial pacing;
HRA ¼ high right atrial; LVEndo ¼ endocardial pacing; RA ¼ right atrial; RADI ¼ LV pressure wire; RV ¼ right ventricular.
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802and right anterior oblique views) to show the position
of the decapolar catheter in relation to the implanted
leads and corroborated this with the 3-dimensional
geometric shell on EAM to conﬁrm its anatomic
position with respect to an AHA 16-segment model.
We conﬁrmed the decapolar catheter tip was in a
stable, ﬁxed position before commencing our pacing
protocol. Prior experience with this equipment has
demonstrated stable electrode localization with
mean change in position of 0.2  1.7 mm (x axis), 0.1 
0.3 mm (y axis), and 0.2  0.6 mm (z axis) (17).
The acute hemodynamic response (AHR) was
measured using an 0.014-inch high-ﬁdelity Certus
RADI PressureWire in the LV as previously described
(11). Atrial pacing 10 bpm greater than the intrinsic
rate was used as baseline and compared with con-
ventional epicardial biventricular pacing via the
implanted LV lead (LVepi1), the temporary LV
lead (LVepi2), and biventricular endocardial pacing
(LVendo) at multiple sites. A delay of 20 s was
respected after changing the pacing protocol and
before any measurement to allow for a steady state
(18,19). Points either side of an ectopic beat were
removed manually after each case. Atrioventricular
delays were ﬁxed at 100 ms and ventriculoventricular
delay was set to 0 ms (simultaneous stimulation from
both right and left ventricular lead poles). For each
pacing site and endocardial position, we measured LV
dP/dtmax (AHR, mm Hg/s), sensed LV electrogram
amplitude (mV), sensed electrical delay (ﬁrstventricular depolarization [Q-LV]) in sinus rhythm
(ms), stimulation-QRS onset (ms), and paced QRS
duration (ms). Default band pass ﬁlter settings of 30
to 300 Hz were used to measure a sensed, bipolar
peak-to-peak voltage signal for the temporary
epicardial LV lead (LVepi2) and endocardial catheter
(LVendo) on the EnSite Velocity NavX system. The
sensed LV signal from the implanted (LVepi1) lead
was obtained through a printed recording from the
pacing systems analyzer with manual calculation of
the peak-to-peak signal. We identiﬁed whether pac-
ing locations were in or adjacent to myocardial scar
identiﬁed on the EAM and CMR and measured the
distance between the LV tip and the central scar zone
for each data point. Field scaling was applied to ac-
count for impedance anomalies and to ensure a 1:1
representation of the patient’s cardiac geometry
(EnSite Velocity NavX system). An AHR was deemed
positive at a pacing location if the dP/dtmax increased
by >10% compared with baseline measurements (20).
STATISTICAL METHODS. Continuous variables with a
Gaussian distribution were described using mean  SD.
Categorical data were described by an absolute number
of occurrences and associated frequency (%). Acute
hemodynamic and electrical data passed the Shapiro-
Wilk test for normality. To account for the clustering
of data andmultiplemeasurementswithin each patient,
a mixed effect model was applied for all data points that
achieved capture. For the best and worst achievable
AHR per patient, in addition to endocardial opposite
TABLE 3 Mean Differences Between Epicardial and Endocardial Datasets
Epicardial Endocardial p Value
Best achievable AHRs in
each patient
(N ¼ 8) (N ¼ 8)
Mean change in AHR (%) 12.64  6.76 25.64  14.74 0.044
Mean QLV (ms) 67  33 95  38 0.216
Mean stimulation-QRS
duration (ms)
19  8 14  5 0.126
Mean paced QRS duration (ms) 167  33 137  26 0.002
Worst AHR in each patient (N ¼ 8) (N ¼ 8)
Mean change in AHR (%) 0.80  6.81 0.93  3.79 0.964
Mean QLV (ms) 68  39 59  15 0.556
Mean stimulation-QRS
duration (ms)
26  21 16  4 0.187
Mean paced QRS duration (ms) 174  32 154  34 0.164
Comparison of LVendo opposite
the corresponding position
of LVepi1 and LVepi2
(N ¼ 16) (N ¼ 16)
Mean change in AHR (%) 7.60  6.3 15.2  10.7 0.014
Mean QLV (ms) 79  34 70  38 0.512
Mean stimulation-QRS
duration (ms)
20  13 16  7 0.214
Mean paced QRS duration (ms) 166  30 137  22 <0.001
Values are mean  SD.
LVendo¼ endocardial pacing; LVepi¼ epicardial pacing; other abbreviations as in Tables 1 and 2.
TABLE 2 Mixed Effect Model
Mean
Difference
95% Conﬁdence
Interval p Value
Change in AHR (%) 4.23 0.52 to 7.93 0.025
QLV (ms) 5.92 18.45 to 6.60 0.354
Stimulation-QRS duration (ms) 3.70 6.50 to 0.88 0.010
Paced QRS duration (ms) 25.45 33.59 to 17.32 <0.001
Mixed effect model for all data points achieving capture comparing epicardial and
endocardial pacing across the dependent variables as shown. A total of 32
epicardial and 87 endocardial data points were compared across 8 patients.
AHR ¼ acute hemodynamic response; QLV ¼ ﬁrst ventricular depolarization
(earliest onset QRS duration on surface 12 lead electrocardiogram) to the nadir
signal on the LV lead electrogram.
TABLE 1 Demographic Data, Pre-CRT and Post-CRT Outcomes
(N ¼ 8)
Age (yrs) 71  7.4
Male (%) 8 (100)
LVEF by 2D echocardiography
Simpson’s biplane before CRT
27  7.4
SDI derived from echocardiography (%) 19
NYHA functional class II/III, before CRT implantation 2/6
Ischemic etiology 8 (100)
Sinus rhythm 8 (100)
QRS duration (m) 140  7
LBBB 7 (88)
LBBB by revised Strauss criteria 3 (38)
Echo responders at 6 months* 2 (25)
LVEF by 2D echo, Simpson’s biplane after CRT 29  7.9
Clinical responders at 6 months† 3 (38)
Values are mean  SD or n (%). *Echocardiographic response using 2D trans-
thoracic echocardiography; conﬁrmed if $15% reduction in end-systolic volume
(ESV) at 6 months’ follow-up compared with before implantation. †Clinical
response to CRT using Packer’s clinical composite score (26).
2D ¼ 2-dimensional; CRT ¼ cardiac resynchronization therapy; LBBB ¼ left
bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York
Heart Association.
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803epicardial AHR data, mean differences between epicar-
dial and endocardial datasets were compared with a
2-tailed, paired t test. Analysis of variance was per-
formed to compare themeans of several groups. Results
were considered signiﬁcant at p < 0.05. Analysis was
performed on PASW Statistics 22 (SPSS Inc., Chicago,
Illinois) and Stata (Stata Corp., College Station, Texas).
RESULTS
Mean native QRS duration was 140  7 ms on surface
ECG. Seven patients (88%) were labelled as having left
bundle branch block; however, only 3 (38%) fulﬁlled
the stricter Strauss criteria (21). All patients, however,
had evidence of myocardial ﬁbrosis on CMR. Patient
demographics are shown in Table 1. Procedural time
was 160  45 min and there were no procedural com-
plications. Patients had severe LV dysfunction with a
mean ejection fraction of 27%, with minimal
improvement at 6 months (ejection fraction 29%). A
total of 135 epicardial and endocardial pacing sites
were tested in 8 patients, 119 of which produced cap-
ture allowing electrical and hemodynamic assessment.
The remaining 16 data points did not capture the
ventricle at maximal (10 V) output and were located in
regions of scar on the contact map. The mean number
of epicardial pacing sites was 5.8  0.5 and the mean
number of LVendo positions was 10.4  4.8, including
sites where LV capture was unsuccessful.
ACUTE HEMODYNAMIC RESPONSE. Using a mixed
effect model analysis for all data points, the mean
AHR of LVendo positions (11.81% [range -7.2% to44.6%]) was signiﬁcantly superior to the mean AHR
of LVepi positions (6.55% [range -11.0% to 19.7%];
p ¼ 0.025) (Tables 2 and 3, Online Table 1, Figure 2).
This was associated with an identical Q-LV between
groups (LVendo 75 ms [range 13 to 161 ms] vs. LVepi
75 ms [range 25 to 129 ms]; p ¼ 0.354) but a shorter
stimulation-QRS duration (LVendo 15 ms [range 7 to
43 ms] vs. LVepi 19 ms [range 5 to 66 ms]; p ¼ 0.010)
and paced QRS duration (LVendo 149 ms [range 95
to 218 ms] vs. LVepi 171 ms [range 120 to 235 ms];
p < 0.001). The mean of the best achievable AHR at
the optimal LVendo site was signiﬁcantly higher than
the optimal LVepi pacing site (25.64  14.74% vs.
12.64  6.76%; p ¼ 0.044). This was associated with
a trend toward a longer Q-LV (95  38 ms vs. 67 
33 ms; p ¼ 0.216), shorter stimulation-QRS duration
FIGURE 3 The Optimal Site for LV Stimulation During Biventricular
Optimal endocardial (left) and epicardial (right) sites (by acute hemodyn
Black circles with a yellow circumference represent the best overall loca
pacing produced the best AHR and the optimal locations were dispersed
AHRs achieved with LVepi pacing; as can be seen the pacing locations w
American Heart Association; ANT ¼ anterior; ANT LAT ¼ anterior lateral;
abbreviations as in Figure 1.
FIGURE 2 Electroanatomic Contact Scar Map With Associated Acute Hemodynamic
Responses During Biventricular Pacing at Different Sites
Anteroposterior (left) and left anterior oblique (right) projections. Data points with a
sensed electrogram amplitude of <0.5 mV were deﬁned as scar (grey), those with voltage
>1.5 mV were deﬁned as healthy tissue (purple), and those points in between were in the
scar border zone with a color range. The best epicardial (LVepi1 and LVepi2) acute he-
modynamic response (% change in dP/dt, mm Hg compared with baseline during biven-
tricular pacing) is displayed alongside 5 endocardial (LVendo) positions. Abbreviations as in
Figure 1.
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804(14  5 ms vs. 19  8 ms; p ¼ 0.126) and a shorter
paced QRS duration (137  26 ms vs. 167  33 ms;
p ¼ 0.002). The difference between the best versus
worst LVepi site was highly signiﬁcant (p ¼ 0.0014) as
it was for best versus worst LVendo (p ¼ 0.0002).
There was a greater difference between the best and
worst AHR with LVendo pacing compared with LVepi
pacing 26.57  12.58 vs. 13.44  9.00; p ¼ 0.03.
There was a nonsigniﬁcant trend toward an improved
AHR with basal compared with mid and apical posi-
tions at all sites (LVepi and LVendo) (base 13.7  11,
mid 8.1  9.8, apex 9.6  12.7; p ¼ 0.07).
OPTIMAL LV SITE LOCATION. Epicardial stimulation
sites were limited according to the coronary venous
anatomy and the best achievable epicardial pacing
locations were therefore conﬁned to the AHA seg-
ments subtended by these veins. In 7 of 8 patients,
the optimal LVepi pacing site was inferolateral/
inferior; in the other patient the basal anterior site
was best in keeping with the belief that pacing from
the inferolateral/inferior wall is the optimal site of
epicardial stimulation in the majority of subjects.
LVendo pacing was not limited to the distribution of
the coronary veins and there was substantial indi-
vidual variation in the optimal site producing the best
AHR (Figure 3).Pacing
amic response [AHR]) for placement of the LV lead in the 8 patients.
tion (LVendo vs. LVepi). This demonstrates that in 6 patients, LVendo
throughout the geometry of the LVendo. Two patients had the best
ere clustered due to the constraints of the epicardial veins. AHA ¼
POST ¼ posterior; POST LAT ¼ posterior lateral; SEPT ¼ septal; other
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805ENDOCARDIAL PACING OPPOSITE EPICARDIAL
LEAD. When the endocardial catheter was placed
opposite the pacing tip of the epicardial lead on the
basis of screening and EAM (Figure 1) (LVepi1/
posterolateral and LVepi2/anterior vein), the AHR
was signiﬁcantly greater (15.2  10.7% vs. 7.6  6.3%;
p ¼ 0.014) despite a similar Q-LV (LVendo 70  38 ms
vs. LVepi 79  34 ms; p ¼ 0.512); however, the paced
QRS duration was signiﬁcantly shorter with LV
endocardial pacing (LVEndo 137  22 ms vs. LVepi
166  30 ms; p < 0.001).
PACING IN SCAR AND LATE ACTIVATED SITES. The
voltage amplitude of the LV sensed electrogram
signal was lower at LVendo compared with LVepi
sites (LVendo 3.84  2.9 mV vs. LVepi 6.68  4.6 mV;
p ¼ 0.002). Of the LVendo stimulation sites, 16 did not
capture and were in scar at a maximal output of 10 V
(conﬁrmed by voltage contact mapping and CMR).
The mean electrogram amplitude within scar sites
with noncapture was 0.18  0.12 mV (n ¼ 16). The
optimal hemodynamic LVendo site was not at the site
of latest electrical activation on the EAM in 6 of 8
patients (Online Table 1).
DISCUSSION
We studied the optimal site for both LVepi and
LVendo stimulation in a cohort of patients with
ischemic heart disease with poor response to con-
ventional CRT. The principal ﬁndings were as follows.
1. Indiscriminate endocardial pacing was superior to
epicardial stimulation, associatedwith a similarﬁrst
ventricular depolarization, shortened stimulation-
QRS duration and shortened paced QRS duration.
2. Optimal achievable endocardial AHR was superior
to the optimal achievable epicardial AHR.
3. There was signiﬁcant interindividual variability of
the position of the optimal LVendo site which was
not predicted by the site of latest electrical acti-
vation on EAM.
4. Pacing within scar on EAM and CMR (both epicar-
dial and endocardial positions) resulted in failure
to capture and a poor AHR.
5. LVendo stimulation at a site approximating LVepi
stimulation resulted in a better AHR and shorter
paced QRS duration despite a similar Q-LV.
COMPARISON WITH PREVIOUS STUDIES. In keeping
with the current study, LVendo pacing has been
found to be superior to conventional CRT in both
ischemic and nonischemic patients (11–13). Derval
et al. (22) found that LVendo pacing was superior to
posterolateral LVepi pacing in nonischemic patientswith signiﬁcant individual variation between the
optimal LVendo pacing sites (22). Spragg et al. (10)
undertook EAM and AHR measurement in 11 pa-
tients with ischemic heart disease and dyssynchro-
nous heart failure at the time of ventricular
tachycardia ablation and found LVendo was superior
to LVepi pacing (10). Our group has shown the supe-
riority of LVendo pacing over conventional CRT in a
group of ischemic and nonischemic patients (11). The
superiority of LVendo pacing over LVepi seems to be
reproducible, but with a signiﬁcant variability in the
optimal site between patients in all the aforemen-
tioned studies (10–12).
The current study has some important differences
and new ﬁndings in comparison with previous
studies that may be of clinical importance. First, our
subjects were selected on the basis of having factors
associated with a suboptimal response to conven-
tional CRT, namely, male sex, ischemic cardiomyop-
athy, myocardial ﬁbrosis (on CMR), and a QRS
duration of 120 to 150 ms. Although all patients were
ischemic in the study by Spragg et al. (10), our sub-
jects had a narrower QRS duration (140  14.9 ms vs.
176  29 ms). In the prior studies, epicardial biven-
tricular pacing was only delivered from a single site in
the posterolateral vein. The superiority of LVendo in
these studies (10–12) may have, therefore, arisen
because the optimal LVepi position was not assessed.
In the current study, we rigorously performed
epicardial pacing from multiple sites (between and
along veins) to ﬁrst determine the optimal LVepi site
(mean 5.8  0.5 sites per subject). For the ﬁrst time
our ﬁndings conﬁrm the superiority of LVendo stim-
ulation, when both LVendo and LVepi sites are sys-
tematically optimized. Figure 2 shows an example of
the superiority of LVendo over LVepi pacing even
when LVepi pacing produced a good AHR.
A notable ﬁnding of the current study was the
superiority of LVendo over LVepi at the same site.
Previous studies have suggested no difference in
ischemic and nonischemic patients, however we
found a signiﬁcant beneﬁt with endocardial pacing
(15.2  10.7% vs. 7.6  6.3%; p ¼ 0.014). Spragg et al.
(10) compared LVendo and LVepi at the same site in 7
patients and found LVendo pacing increased dP/dtmax
by 36% from baseline compared with 29% via LVepi
although this increase was not statistically signiﬁ-
cant. These differences may be related to the
different population studied, but also that we
assessed and optimized LVepi pacing in both the
anterior and posterolateral regions. Our data are in
keeping with both animal studies (13) and a computer
modelling study from our group (14). Finally, our
patients had CMR data that could be correlated with
FIGURE 4 Local Activation Map, Correlation With Myocardial Fibrosis on CMR and Associated AHR at Different Locations in 1 Patient
(Top) Electroanatomic (EAM) contact map showing local activation in the same subject as in Figure 2. White signiﬁes earliest activation and
blue latest activation, demonstrating the basal lateral region as the site of latest electrical delay. In this case, the optimal AHR (star) matched
the site of latest electrical delay, which was distant from ischemic scar. (Bottom) Cardiac MR (CMR), late gadolinium enhancement sequences in
the short axis, mid ventricular (left), 2-chamber (middle), and 4 chamber (right) views. The white arrows demonstrate areas of thin walled
myocardium with associated subendocardial myocardial ﬁbrosis, corresponding to an left anterior descending (LAD) territory myocardial
infarction. There is a close correlation between the scar demonstrated on the EAM and that displayed with CMR. (Right) AHA bulls-eye plot
diagram with scar (derived from CMR and EAM) spray painted in grey (anterior, LAD infarct). All different positions for the LV lead are
demonstrated (both epicardial and endocardial) with the legend detailing whether the associated AHR with biventricular pacing was <10% or
>10% improvement from baseline. Pacing around the anterior regions of scar corresponded to a poor AHR, compared with much better AHRs in
sites out of scar. Abbreviations as in Figures 1 and 3.
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806the results of EAM, which was not the case in the
aforementioned studies (Figure 4).
SCAR AND ELECTRICAL ACTIVATION. In the study
from Spragg et al. (10), optimal LVendo pacing sites
typically were located far from regions of dense scar
and in 8 of 11 subjects optimal LVendo sites were not
at the site of latest activation. For most patients,
optimal pacing sites were located in regions activated
neither extremely early nor late during ventricular
excitation. The authors concluded the lack of corre-
lation between latest endocardial activation sites and
optimal pacing sites may reﬂect a disconnect between
electrical and mechanical activation, the impact of
regions of slow conduction, and lines of conduction
block on optimal pacing sites. Our results support this
theory, conﬁrmed by failure to capture the LV at
maximal voltage at 16 endocardial sites within scar
(on CMR and EAM). Furthermore, the optimal hemo-
dynamic LVendo site did not necessarily correlate
with the site of latest electrical activation in 6 of 8
patients, as determined on the EAM activation map.In keeping with this ﬁnding, the Q-LV at the optimal
LVendo sites were not signiﬁcantly longer than those
at the optimal LVepi site. It seems likely that, on the
basis of our and other prior ﬁndings, the latest acti-
vating site is not necessarily the optimal site to pace
with respect to improved hemodynamics. This may
be due to localized areas of slow conduction with
islands of viable tissue within areas of scar that acti-
vate late (and therefore have a long Q-LV). Likewise,
when stimulation is performed at that site, impulse
propagation is also slow out of this area and does not
result in effective resynchronization. An example of
this is seen in Figure 5 in a patient with a large
circumferential midventricular and apical infarct with
areas of late activating tissue within the scar. It is
possible that seeking a late activated site may be
beneﬁcial, but only if conduction out of that site is
not also delayed or blocked by regions of scar. This is
analogous to a Goldilocks effect where the optimal
site in ischemic patients because of scar/slow con-
duction may be not too early, not too late but just
right, somewhere in between the two.
FIGURE 5 Local Activation Map and Associated Acute Hemodynamic Response in a Patient With Electrical Latency Within a
Large Area of Scar
Dilated, globular heart with a heavy burden of myocardial scar. Earliest activation is white and latest activation blue/purple. In this case,
LVendo locations were not superior to conventional LVepi with respect to the AHR. The point of latest electrical activation in this case is around
the anteroseptum, most likely as a result of slow activation spreading and encircling a large region of scar. Although these sites are the latest
activated they will not produce a good AHR because they are in scar and may explain why the latest activated site is not always the optimal
pacing site. Abbreviations as in Figures 1 and 3.
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807MECHANISM OF BENEFIT OF LVendo PACING. In-
discriminate stimulation of the LVendo produced a
superior hemodynamic effect compared with con-
ventional epicardial stimulation. The beneﬁt of
LVendo pacing may be related to the lack of coronary
venous constraints and the ability to access all re-
gions of the myocardium resulting in the ability to
obtain the best achievable AHR. The broad variation
in hemodynamic response and notable lack of capture
in areas of scar, clearly visible on CMR/EAM suggest a
targeted approach avoiding scar may be helpful.
The superiority of the optimal LVendo over the
optimal LVepi AHR at the same site with an associ-
ated shorter paced QRS duration may support more
rapid activation of the ventricles by fast conducting
tissue including the His-Purkinje network (14,15).
Equally, other mechanisms (not examined in this
manuscript) such as a shorter, more concave path for
electrical conduction with LVendo pacing may also be
contributing to our ﬁndings.
CLINICAL RELEVANCE. CRT nonresponse occurs in
one-third of patients receiving this treatment and is
higher in ischemic patients with myocardial ﬁbrosis
and modest QRS prolongation (120 to 150 ms). Stra-
tegies to improve response in this group are required.The recently published ALSYNC (ALternate Site Car-
diac ResYNChronization) study demonstrated the
feasibility and safety of LV endocardial CRT deliv-
ered, through the atrial trans-septal approach (23). In
138 patients with either prior suboptimal response to
conventional CRT, failure of LV lead implantation or
suboptimal coronary venous anatomy the inves-
tigators achieved a high implant success rate (89.4%),
with stable pacing parameters and an 82.2% freedom
from complications at 6 months. Furthermore, clinical
and echocardiographic improvement was 59% and
55%, respectively, in a group with prior nonresponse,
which is highly encouraging. Targeting the optimal
site for LV stimulation remains an important issue
given the marked degree of variability between pa-
tients. Our results suggest that CMR may be helpful in
this respect especially in avoiding areas of scar, which
result in failure to capture or poor resynchronization.
Targeting a late but not necessarily latest activating
site (i.e., late but not within the scar) is achievable
with CMR techniques that give information regarding
myocardial activation/contraction patterns as well as
pinpointing scar (24).
The ALSYNC study used an empirical approach to
LV lead placement and despite this reported a sig-
niﬁcant improvement compared with conventional
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Biventricular pacing delivered through LV endocardial
stimulation seems to provide superior acute hemody-
namics and a shortening of the paced QRS duration
compared with LV epicardial stimulation in the equiv-
alent territory. A lack of coronary venous constraint
and preferential access to fast conducting tissue are
likely to under pin the superiority of this method for
delivery of CRT. Cardiac magnetic resonance–derived
myocardial ﬁbrosis corroborates with scar derived from
electroanatomicmaps andmay be helpful in guiding LV
lead placement. Furthermore, targeting nonscarred
segments identiﬁed through cardiac magnetic reso-
nance cine sequences can aid optimal lead placement in
an attempt to improve response to CRT.
TRANSLATIONAL OUTLOOK: Biventricular pacing
has been offered to selected patients with heart fail-
ure for more than 20 years; however, a signiﬁcant
proportion of individuals receiving this therapy do not
derive signiﬁcant clinical beneﬁt. Certain groups such
as male patients with ischemic etiology, myocardial
scar and QRS duration of 120 to 150 ms have a high
prevalence for poor response and alternative options
for improving the effectiveness of CRT are urgently
required. Recently, animal and human data have
suggested superior hemodynamics and shorter elec-
trical activation for endocardial versus epicardial LV
stimulation in delivery of biventricular pacing. Clinical
studies have demonstrated the feasibility of endo-
cardial LV stimulation through transatrial septal and
transventricular septal approaches, as well as leadless
LV pacing in combination with an implanted right-
sided system. Coupled with advanced cardiac imaging
to guide LV placement away from areas of scar and
toward those activating lately, CRT delivery through
permanent LV endocardial stimulation may represent
a new method to improve outcomes for heart failure
patients over the coming decades.
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808epicardial pacing. Our results support image guidance
on the basis that a broad range of AHR values were
obtained and therefore not all endocardial positions
are equal in this cohort. Although an indiscriminate
approach showed endocardial pacing was superior to
epicardial pacing (Table 2), an even greater AHR was
achievable when both epicardial and endocardial
sites were optimized. Therefore, an image-guided,
targeted approach could be a strategy for identifying
the optimal location for LV lead stimulation. CMR
techniques do, however, require further evaluation to
assess their merit in guiding endocardial pacing sites
and techniques which allow CMR derived scar and
mechanical activation to be fused onto live ﬂuoros-
copy for epicardial LV lead guidance may also be used
for LVendo lead guidance (18,25).
STUDY LIMITATIONS. The main limitation of the
current study is the low number of patients studied.
Due to the highly invasive nature of the study and the
difﬁculty in identifying a group of nonresponders,
this is understandable. The protocol was, however,
extremely rigorous with a large number of data points
(135 endocardial and epicardial pacing positions). The
EAM study is invasive and not likely to be of use in
routine clinical practice. Due to the length of the
procedures no changes in atrioventricular or ven-
triculoventricular delay were studied and it is
possible that such manipulations may have produced
a different response. Finally, hemodynamic response
may not necessarily translate to chronic response to
CRT and therefore longer term studies are required;
results from a multicenter, randomized, controlled
trial, RADI-CRT (Pressure Wire Guided Cardiac
Resynchronisation Therapy; NCT01464502) may help
to clarify this.
CONCLUSIONS
Our ﬁndings suggest that, in ischemic patients with
poor CRT response, endocardial pacing is superior to
epicardial pacing with an even greater response
achievable with optimization for each set of pro-
tocols. The mechanism of beneﬁt may be due to the
ability to access more optimal sites that cannot be
reached by the constraints of the CS anatomy.
Furthermore, guidance to the optimal LV pacing site
may be aided by modalities such as CMR to target
nonscarred and delayed activating sites.
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